Literature DB >> 24432206

Primary oral Penicillium marneffei infection diagnosed by PCR-based molecular identification and transmission electron microscopic observation from formalin-fixed paraffin-embedded tissues.

Xia Hua1, Ruifeng Zhang1, Hanjun Yang1, Song Lei2, Yizhi Zhang1, Yuping Ran1.   

Abstract

We report a case of primary oral Penicillium marneffei infection in a 39-year-old man without HIV infection. Although fungal culture was negative, the patient was finally confirmed to have P. marneffei infection by PCR-based molecular identification and transmission electron microscopic observation from formalin-fixed, paraffin-embedded tissues. The patient was cured with taking itraconazole for 3 months.

Entities:  

Keywords:  Leishmaniasis; Oral; Penicillium marneffei; Polymerase chain reaction; Transmission electron microscope

Year:  2012        PMID： 24432206      PMCID： PMC3885956          DOI： 10.1016/j.mmcr.2012.10.008

Source DB:  PubMed          Journal:  Med Mycol Case Rep        ISSN： 2211-7539


  17 in total

1.  Case Report. Oro-facial manifestations of Penicillium marneffei infection in a Thai patient with AIDS.

Authors:  P Khongkunthian; W Isaratanan; L P Samaranayake; H R Gelderblom; P A Reichart
Journal:  Mycoses       Date:  2002-11       Impact factor: 4.377

2.  The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica.

Authors:  H Akuffo; M Dietz; S Teklemariam; T Tadesse; G Amare; T Y Berhan
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Jul-Aug       Impact factor: 2.184

3.  Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole.

Authors:  A S al-Fouzan; Q A al Saleh; N M Najem; A I Rostom
Journal:  Int J Dermatol       Date:  1991-07       Impact factor: 2.736

4.  Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients.

Authors:  T Sirisanthana; K Supparatpinyo; J Perriens; K E Nelson
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

5.  Chronic pulmonary paracoccidioidomycosis masquerading as lymphangitis carcinomatosa.

Authors:  S Bowler; A Woodcock; P Da Costa; M Turner-Warwick
Journal:  Thorax       Date:  1986-01       Impact factor: 9.139

6.  Treatment of cutaneous leishmaniasis with oral itraconazole.

Authors:  E Van den Enden; A Van Gompel; A Stevens; N Vandeghinste; D Le Ray; P Gigase; K De Beule; J Van den Ende
Journal:  Int J Dermatol       Date:  1994-04       Impact factor: 2.736

7.  Ultrastructural observations on Penicillium marneffei in natural human infection.

Authors:  Y F Chan; T C Chow
Journal:  Ultrastruct Pathol       Date:  1990 Sep-Oct       Impact factor: 1.094

8.  Use of itraconazole in the treatment of mucocutaneous leishmaniasis: a pilot study.

Authors:  V S Amato ; A R Padilha; A C Nicodemo; M I Duarte; M Valentini; D E Uip; M Boulos; V A Neto
Journal:  Int J Infect Dis       Date:  2000       Impact factor: 3.623

9.  Cutaneous leishmaniasis. Treatment with itraconazole.

Authors:  G Albanese; P Giorgetti; L Santagostino; D Crippa; G Sala
Journal:  Arch Dermatol       Date:  1989-11

10.  Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.

Authors:  V S Amato; F F Tuon; R Imamura; R Abegão de Camargo; M I Duarte; V A Neto
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-05-04       Impact factor: 6.166
View more
  2 in total

1.  Microsporidial keratitis retrospectively diagnosed by ultrastructural study of formalin-fixed paraffin-embedded corneal tissue: a case report.

Authors:  Satoru Ueno; Hiroshi Eguchi; Fumika Hotta; Masahiko Fukuda; Masatomo Kimura; Kenji Yagita; Takashi Suzuki; Shunji Kusaka
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-06-10       Impact factor: 3.944

2.  A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis.

Authors:  Thanyarak Wongkamhla; Piriyaporn Chongtrakool; Anupop Jitmuang
Journal:  BMC Infect Dis       Date:  2019-12-05       Impact factor: 3.090
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.